Figure 4 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

Résumé fourni par la source

CD4+ T cells sensitize qM tumors lacking CD73 and MHC-I to anti-CTLA4 ICB. A, Schema and tumor kinetics for CD73 and B2M DKO tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. B, Schema and tumor kinetics for CD73 and B2M DKO tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. C and D, Representative immunofluorescence images of primary tumor sections obtained from (B) stained for CD4 (red), CD8 (white), and DAPI (blue) at 63× magnification. D, Bar graph represents quantification of CD4+ T cells in each high-power field (HPF) at 63× magnification for the indicated treatment groups. 3–5 fields of view from the tumor interior were obtained for each tumor. Data represent three independent experiments, with n = 3–5 mice in each group. E, Schema and tumor kinetics for CD73 and B2M DKO tumor-bearing mice treated with the indicated antibodies. Data represent two independent experiments in which n = 3–9 for each group. F, Schema and tumor kinetics for CD73 and B2M DKO tumors propagated in WT or CD4-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. G, Schema and tumor kinetics for CD73 and B2M DKO tumor-bearing mice treated with the indicated antibodies. Responders were rechallenged with the same cell line as indicated with or without treatment with anti-CD4. Data represent three independent experiments in which n = 3–7 for each group. A, B, and E–G, Data represent the SEM, two-way ANOVA, **, P < 0.01; ****, P < 0.0001. D, Data represent the SEM, two-tailed unpaired t test, **, P < 0.01. Scale bars are 100 μm.